Emerging Company Profiles
Satellos is moving to start a double-blinded Phase II trial of its experimental Duchenne muscular dystrophy candidate that looks to mimic the effects of dystrophin on muscle stem cells.
The agency is expected to give its final verdict on elamipretide by the end of September.
Emerging Company Profile: Axelyf raises $2.6m seed round for lipid nanoparticle delivery platform on heels of end to US federal support for mRNA vaccines.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.
Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.
Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.
Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.
Emerging Company Profile: Danish group Vesper Bio is advancing an oral sortilin inhibitor in frontotemporal dementia, and is aiming to get to market in a similar timeframe to its much larger rivals.
Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.
Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.
Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.
Emerging Company Profile: Seaport Therapeutics believes its technology can alter old drugs to remove their flaws. Just how closely can it follow the example set by Karuna?
Emerging Company Profile: Encouraging, but early, data on a gamma-delta T-cell therapy could position Kiromic BioPharma for deal-making.
Emerging Company Profile: The Swedish biotech’s CEO Maria Lisa Knudsen believes that the firm’s two technologies make it an attractive prospective partner for big pharma.
Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.
Emerging Company Profile: Armed with a new tranche of funding, the Danish group is aiming to improve the lot of infertile couples by altering the microbiome of patients with dysbiosis.
Emerging Company Profile: The US biotech is advancing a pipeline of precision medicines targeting menin and farnesyltransferase for liquid and solid tumors, respectively, building on the work of two pioneering companies in the KRAS space.
Emerging Company Profile: The US biotech SpyGlass is gearing up for a Phase I/II trial in glaucoma after recently closing a $90m fundraising to help advance its intraocular delivery platform to address poor treatment adherence in chronic eye diseases.